Læknablaðið - 15.04.2000, Side 21

FRÆÐIGREINAR / KRANSÆÐAVÍKKANIR Á ÍSLANDI
M, Cerisano G, et al. Restenosis after coronary stenting in
current clinical practice. Am Heart J 1998; 135:510-8.
37. Schwartz RS. Pathophysiology of restenosis: interaction of
thrombosis, hyperplasia, and/or remodeling. Am J Cardiol
1998; 81(7A): 14E-17E.
38. Califf RM, Ohman EM, Frid DJ, Fortin DF, Mark DB, Hlatky
MA, et al. Restenosis: The Clinical Issues. In: Topol EJ, ed.
Textbook of Interventional Cardiology. London: WB Saun-
ders Company; 1999: 363-94.
39. Sirnes PA, Molstad P, Myreng Y, Golf S. Predictors for reste-
nosis after angioplasty of chronic coronary occlusions. Int J
Cardiol 1998; 67:111-8.
40. Tardif JC, Cote G, Lespérance J, Bonrassa M, Cambert J,
Doucet S, et al. Probucol and multivitamins in the prevention
of restenosis after coronary angioplasty. Multivitamins and
Probucol Study Group [see comments]. N Engl J Med 1997;
337:365-72.
41. Kosuga K, Tamai H, Ueda K, Hsu YS, Ono S, Tanaka S, et al.
Effectiveness of tranilast on restenosis after directional
coronary atherectomy. Am Hear J 1997; 134: 7712-8.
42. Teirstein PS, Massullo V, Jani S, Russo RJ, Cloutier DA,
Schatz RA, et al. Two-year follow-up after catheter-based
radiotherapy to inhibit coronary restenosis [see comments].
Circulation 1999; 99:243-7.
43. Hamburger JN, Serruys PW. Treatment of thrombus con-
taining lesions in native coronary arteries and saphenous vein
bypass grafts using the AngioJet Rapid Thrombectomy Sys-
tem. Herz 1997; 22:318-21.
44. Grube E, Gerckens U, Miiller R, Rowold S. The SAFE study:
Multicenter evaluation of a protection catheter system for
distal embolization in coronary venous bypass grafts (SVGs).
Am J Cardiol 1999; 84/Suppl. 6A: 19P.
45. Yock PG, Fitzgerald PJ. Intravascular ultrasound: state of the
art and future directions. Am J Cardiol 1998; 81(7A): 27E-
32E.
46. Colombo A, Kobayashi Y. Intravascular ultrasound-guided
PTCA [editorial comment]. Eur Heart J 1998; 19:196-8.
47. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho
KKL, et al. A clinical trial comparing three antithrombotic-
drug regimens after coronary stenting (STARS-trial). N Engl J
Med 1998; 339:1665-71.
48. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S,
et al. Effectiveness of clopidogrel and aspirin versus ticlopi-
dine and aspirin in preventing stent thrombosis after coronary
stent implantation. Circulation 1999; 99:2364-6.
49. The EPIC Investigators. Use of monoclonal antibody directed
against the platelet glycoprotein Ilb/IIIa receptor in high-risk
coronary angioplasty. N Engl J Med 1994; 330: 956-61.
50. Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA,
Timmis GC, et al. Sustained suppression of ischemic complica-
tions of coronary intervention by platelet GP Ilb/IIIa bloc-
kade with abciximab: one-year outcome in the EPILOG trial.
Evaluation in PTCA to Improve Long-term Outcome with
abciximab GP Ilb/IIIa blockade. Circulation 1999; 99: 1951-8.
51. EPISTENT Investigators. Randomized placebo controlled
and balloon angioplasty controlled trial to assess safety of
coronary stenting with use of platelet glycoprotein Ilb/IIIa
blockade. Lancet 1998; 352: 87-92.
52. Montalescot G. ADMIRAL study: Abciximab with PTCA
and Stent in acute myocardila infarction. Late-breaking clini-
cal trials in interventional cardiology. Presented at the Ameri-
can Collage of Cardiology 48th Scientific Session, March 7-10,
1999. http://www.medscape.com
53. Califf RM. Glycoprotein Ilb/IIIa blockade and thrombolysis:
early lessons from SPEED and GUSTO IV trials. Am Heart J
1999; 138: S12-5.
Nýr doktor í læknisfræði
Þann 17. september síðastliðinn lauk Dóra Lúð-
víksdóttir doktorsprófi í læknisfræði frá Uppsalahá-
skóla. Doktorsritgerðin ber titilinn Airway Respon-
siveness and Exhaled Nitric Oxide. Studies in asthma
and Sjögren's syndrome. Ritgerðin fjallar um loft-
vegabólgu og berkjuauðreitni hjá sjúklingum með
astma og einstaklingum með heilkenni Sjögrens.
Rannsökuð voru tengsl berkjuauðreitni og köfnunar-
efnisoxíðs (NO) í útöndunarlofti við loftvegaein-
kenni og bólguþætti í blóði. Agrip af ritgerðinni fer
hér á eftir.
In this thesis, four different types of provoca-
tion agents: methacholine, adenosine 5'-mono-
phosphate (AMP), cold air and dry powder
mannitol were used to study different aspects of
the airway responsiveness profile in asthma and
Sjögren's syndrome. Exhaled nitric oxide (NO)
and markers of eosinophil activation, serum eosi-
nophil peroxidase (S-EPO) and serum eosinophil
cationic protein (S-ECP) were measured.
The main findings of this research are that
atopic patients with asthma were significantly
more hyperresponsive to AMP than nonatopic
asthmatic subjects and patients with Sjögren's
syndrome. In atopic subjects with asthma, the air-
way responsiveness to AMP was correlated with
markers of eosinophil activation S-EPO and S-
ECP. Furthermore, hyperresponsiveness to cold
air was more common in atopic asthmatics com-
pared with patients with Sjögren's syndrome.
Exhaled NO was almost twice as high in
patients with Sjögren's syndrome and atopic asth-
matics compared with healthy controls. In atopic
asthmatics exhaled NO was significantly correla-
ted with airway responsiveness to methacholine
and was due to an increased NO flux from the
airways but not the alveoli. After inhalation of dry
powder mannitol the levels of exhaled NO de-
creased in asthmatics, but increased in healthy
individuals.
In conclusion, atopic and nonatopic subjects
with asthma and patients with Sjögren's syndrome
have different airway responsiveness profiles for
AMP and cold air. Exhaled NO is elevated in
patients with Sjögren's syndrome and in atopic
asthmatic subjects while nonatopic asthmatics
have normal levels. Using a new bronchial provo-
cation test with dry powder mannitol we showed
that healthy subjects can release NO after manni-
tol provocation, wheras asthmatics can not. More
than one type of bronchial provocation may be
required to detect different aspects of the airway
hyperresponsiveness profile.
Dóra starfar sem sérfræðingur við lungnalækn-
ingaskor lyflækningasviðs Landspítala Vífilsstöð-
um.
Dr. Dóra Lúðvíksdóttir.
Læknablaðið 2000/86 249